Neumora Therapeutics(NMRA) - 2024 Q3 - Quarterly Results

EXHIBIT 99.1 Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first hal ...